MENT and Tamoxifen Interaction: Synergistic | Peptide Database

FDA-approved indication. Nandrolone decanoate stimulates erythropoietin production and directly enhances erythropoiesis, increasing red blood cell mass in patients with chronic kidney disease-associated anemia. Used particularly in patients who respond poorly to erythropoiesis-stimulating agents. Historical use in aplastic anemia to stimulate red blood cell, white blood cell, and platelet production. Largely superseded by modern therapies but still considered in resource-limited settings. Nandrolone increases collagen synthesis (type I and III), synovial fluid production, and overall connective tissue integrity. Widely reported to reduce joint pain and improve function in individuals with degenerative joint conditions or training-related joint stress. The mechanism involves direct stimulation of fibroblast activity and increased procollagen mRNA expression. Nandrolone has been studied for the treatment and prevention of osteoporosis, particularly in postmenopausal women and hypogonadal men. It increases bone mineral density through direct osteoblast stimulation and suppression of osteoclast activity. Used in HIV/AIDS-associated wasting, cancer cachexia, and chronic illness-related sarcopenia to preserve and restore lean body mass. Demonstrated significant improvements in lean mass, strength, and functional capacity in clinical trials. Dose-dependent increases in lean body mass and muscle cross-sectional area. At therapeutic and supraphysiological doses, nandrolone promotes substantial gains in skeletal muscle with less water retention than equianabolic doses of testosterone. Increases in maximal strength across compound movements, driven by enhanced protein synthesis, nitrogen retention, and glycogen storage. Effects are dose-dependent and most pronounced when combined with resistance training. Nandrolone has been used to accelerate recovery from major surgery, severe burns, and debilitating injuries by promoting positive nitrogen balance, collagen deposition, and lean tissue preservation during catabolic states. Preclinical evidence suggests nandrolone may enhance tendon healing by increasing collagen fiber organization and cross-linking. Clinical applications for tendon repair remain investigational but are supported by its known collagen-stimulating properties.

Join others researching Trazodone — share findings, ask questions, and learn from real experiences Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that was originally approved by the FDA in 1981 for the treatment of major depressive disorder. However, its clinical use has shifted dramatically over the decades. Today, trazodone is prescribed almost exclusively at low doses as a sleep aid rather than as an antidepressant, making it one of the most commonly prescribed medications for insomnia in the United States. Its popularity stems from the fact that it is non-habit-forming, does not carry the dependence risk associated with benzodiazepines or Z-drugs, and can be used long-term without tolerance development. Trazodone has become particularly well-known in the bodybuilding and performance-enhancement community as a go-to solution for managing insomnia caused by trenbolone and other 19-nortestosterone derivatives, which are notorious for disrupting sleep architecture. Unlike many sleep medications, trazodone actually improves slow-wave sleep (deep sleep) rather than simply inducing sedation, which makes it especially valuable for recovery-focused athletes. Trazodone's sleep-promoting effects arise from a combination of pharmacological actions across multiple receptor systems. At low doses (25-100 mg), the dominant mechanism is potent antagonism of 5-HT2A serotonin receptors, which promotes slow-wave sleep and reduces sleep latency. Trazodone also blocks histamine H1 receptors, contributing to its sedative properties, and antagonizes alpha-1 adrenergic receptors, which produces additional drowsiness and accounts for the orthostatic hypotension sometimes observed. At higher doses used for depression (150-400 mg), serotonin reuptake inhibition (SRI) becomes more relevant, increasing serotonergic tone in a manner similar to SSRIs but with a distinct receptor profile. The compound is metabolized primarily by CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP), which has serotonin agonist properties. The dose-dependent shift in pharmacological profile explains why trazodone is sedating at low doses but can be activating or cause more typical serotonergic side effects at antidepressant doses.